Merck KGaA/SFJ's Abituzumab Evaluated For Left-Sided Metastatic Colon Cancer
Executive Summary
SFJ Pharmaceuticals has taken on the late-stage clinical development of Merck KGaA's previously stalled MAb abituzumab, sharing the financial risk and evaluating patients with left-sided colorectal cancer.
You may also be interested in...
Pfizer's Axitinib Disappoints As RCC Adjuvant Therapy
An interim analysis has recommended stopping the Phase III ATLAS study because axitinib was failing to show it extended disease-free survival when used as adjuvant therapy in earlier-stage renal cell carcinoma patients. However, combination studies of axitinib with immuno-oncology agents will continue.
Keeping Track Of Good News For AstraZeneca, Pfizer, Promius, And Sunovion
NDA and BLA submission news from our US FDA Performance Tracker.
Erbitux Sales Growth Will Bounce Back, Says Merck KGaA
Later-than-expected tenders in Europe and emerging clinical data are expected to allow sales of best-seller Erbitux to start growing again after an unexpected first-quarter decline, as the German company starts late-stage studies with PD-L1 inhibitor avelumab in its collaboration with Pfizer.